DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus, a leader in sickle cell disease treatment, signs agreement with Cardinal Health to solidify distribution network for Endari™ (L-glutamine oral powder)
Emmaus Life Sciences, Inc. announces it has entered into a distribution agreement with Cardinal Health (Cardinal). The agreement makes Endari™ (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older, available nationwide to pharmacies that utilize Cardinal as their distributor. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Cardinal Health ranks among the top 25 on the Fortune 500.
Since launching Endari, the first U.S. FDA approved sickle cell treatment in 20 years, Emmaus has brought this therapy to patients in 36 states, Washington DC and Puerto Rico. In addition to the distributors already in place, this agreement with Cardinal will further broaden Endari’s distribution, with the potential to reach many more patients suffering from the acute complications associated with sickle cell disease, such as pain and frequent hospitalizations.
Related Content
-
news & eventsFDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell D...Emmaus Life Sciences Inc. announced toda...
-
news & eventsEmmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
news & eventsSickle Cell Treatment Endari Now Available in the United StatesEmmaus Life Sciences has announced that ...
-
news & eventsL-glutamine Oral Powder Significantly Reduces Acute Complications of Sickle Cell DiseaseApproved by the US Food and Drug...
-
news & eventsEmmaus, a leader in sickle cell disease treatment, signs agreement with McKesson to expand distribution network for ...Emmaus Life Sciences, Inc., anno...
-
education & researchPhase 3 study of L-Glutamine in sickle cell disease: Analyses of time to first and second crisis and average cumulat...A Phase 3, double-blind, randomized, pla...
-
education & researchL-Glutamine for sickle cell anemia: More questions than answersIn 2017, the Food and Drug Administratio...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.